A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors

Phase 1 Completed 64 enrolled Eisai Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) and to explore the safety and anti-tumor activity of E7389 in combination with carboplatin in patients with advanced solid tumors.

Timeline

Start: 2006-10
Primary completion: 2011-11
Completion: —

Publications

Goel S, Swami U, Kumar K, Dittrich C, Reyderman L, Jain M, Aisner J, Song J, Petrylak DP. A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer. Cancer Chemother Pharmacol. 2019 Sep;84(3):567-578. doi: 10.1007/s00280-019-03877-4. Epub 2019 Jun 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Carboplatin	Small molecule	6 unknown	Intravenous
Subject	Eribulin	Small molecule	0.7 mg/m2	Intravenous
Subject	Eribulin	Small molecule	1.1 mg/m2	Intravenous
Subject	Eribulin	Small molecule	1.4 mg/m2	Intravenous

A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications